Stay updated on Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.2, and the Revision: v3.3.1 note has been removed. This appears to be a minor site version update with no impact on the study details, eligibility criteria, or user-facing content.
    Difference
    0.1%
    Check dated 2025-12-01T16:38:08.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A new revision label 'Revision: v3.3.1' has been added. Related topics including 'Prostate cancer', 'MedlinePlus Genetics', and 'Revision: v3.2.0' have been removed.
    Difference
    0.2%
    Check dated 2025-11-24T12:42:38.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Added Prostate cancer and MedlinePlus Genetics as related topics. Removed the government funding status notice regarding NIH operations (the NIH Clinical Center).
    Difference
    0.6%
    Check dated 2025-11-17T06:24:06.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The related topics section no longer lists Prostate Cancer and MedlinePlus Genetics.
    Difference
    0.2%
    Check dated 2025-11-10T03:26:25.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    No significant additions or deletions were detected on the NCT03061539 study page. The content remains focused on the study overview, eligibility criteria, and study plan.
    Difference
    0.4%
    Check dated 2025-11-03T00:59:45.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    Added related topics: Prostate cancer and MedlinePlus Genetics to the page for indexing and contextual information. This does not change the study details, eligibility criteria, or outcomes.
    Difference
    0.2%
    Check dated 2025-10-26T20:31:52.000Z thumbnail image

Stay in the know with updates to Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.